	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 2
Objectives	3	State specific objectives, including any prespecified hypotheses Page 2, paragraph 3
Methods		
Study design	4	Present key elements of study design early in the paper Page 4, paragraph 3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
		Location - page 4, paragraph 1
		Dates - page 4, paragraph 2
		Exposure - page 5, paragraph 2
		Follow-up - page 5, paragraph 1
		Data collection - page 4, paragraph 3 & paragraph 4
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up
		Eligibility criteria - page 4, paragraph 2
		Selection of participants - page 4, paragraph 3
		Case-control study—Give the eligibility criteria, and the sources and methods of
		case as certainment and control selection. Give the rationale for the choice of cases and controls
		Cross-sectional study—Give the eligibility criteria, and the sources and methods of
		selection of participants
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed
		N/A
		Case-control study—For matched studies, give matching criteria and the number of
		controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
		Outcomes - page 4, paragraph 4
		Outcome diagnostic criteria - page 5, paragraph 1
		Exposures/predictors - page 5, paragraph 2
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there
		is more than one group
		Outcomes - page 5, paragraph 2
Bias	9	Describe any efforts to address potential sources of bias N/A

Study size	10	Explain how the study size was arrived at
		Page 4, paragraph 2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
		Page 5, paragraph 2
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		Statistical methods: page 6, paragraph 2
		Confounding: page 6, paragraph 2
		(b) Describe any methods used to examine subgroups and interactions
		N/A
		(c) Explain how missing data were addressed
		Page 6, paragraph 2
		1 age 6, paragraph 2
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed N/A
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed N/A  Case-control study—If applicable, explain how matching of cases and controls was
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed N/A  Case-control study—If applicable, explain how matching of cases and controls was addressed
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed N/A  Case-control study—If applicable, explain how matching of cases and controls was addressed  Cross-sectional study—If applicable, describe analytical methods taking account of

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed  Page 7, paragraph 1	
		(b) Give reasons for non-participation at each stage  N/A	
		(c) Consider use of a flow diagram N/A	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  Page 7, paragraph 2	
		(b) Indicate number of participants with missing data for each variable of interest  Appendix 1	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)  Page 7, paragraph 1	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time Page 7, paragraph 1	
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included  Page 7, paragraph 2, Page 8 paragraphs 1	
		(b) Report category boundaries when continuous variables were categorized	
		See methods: page 5, paragraph 2  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  N/A	
Otheranalyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  Page 7, paragraph 2	
Discussion			
Key results	18	Summarise key results with reference to study objectives Page 9, paragraphs 1-3; page 10, paragraphs 1-2	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.  Discuss both direction and magnitude of any potential bias  Page 10, paragraph 1	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence  Pages 9-11	
Generalisability	21	Discuss the generalisability (external validity) of the study results  Page 11, paragraph 2	
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,	

for the original study on which the present article is based See title page

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist itemand gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.